[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intraductal-papillary-mucinous-neoplasm-of-pancreas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intraductal-papillary-mucinous-neoplasm-of-pancreas":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,78,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100628610","management-of-pancreatic-cystic-lesions-using-artificial-intelligence-based-on-eus-and-multimodal-data-100628610",false,"NCT07463872","Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data","A Multimodal Artificial Intelligence Model for Subtyping Diagnosis and Clinical Management of Pancreatic Cystic Lesions Based on Endoscopic Ultrasound and Clinical Information","Inclusion criteria:\n\n* Patients whose EUS results indicates pancreatic cystic or cystoid lesions;\n* Mucinous lesions: including mucinous cystic neoplasm (MCN), intraductal papillary mucinous neoplasm (IPMN);\n* Non-mucinous lesions: including pancreatic pseudocyst, serous cystic neoplasm (SCN), cystic neuroendocrine tumor (cNET).\n\nExclusion criteria:\n\n* Patients whose age is less than 18 years old;\n* Patients who have undergone pancreatic surgery before the EUS examination;\n* Patients who have received chemotherapy and radiotherapy for pancreatic tumors before the EUS examination;\n* Pathological results indicate that pancreatic lesions are metastatic lesions from other sites;\n* Patients whose EUS images or reports are missing;\n* EUS image quality does not meet the requirements for review, such as blurry imaging or containing artifacts, biopsy needles, measuring scales, or other additional annotations that are not part of the original EUS image;\n* Patients whose final diagnosis is unclear.","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","OBSERVATIONAL","The primary objective is to construct a multimodal AI model (Cyst-AI) based on EUS images and clinical data such as imaging features(CT or MRI) and laboratory tests to assist endoscopists in the diagnosis of pancreatic cystic lesions(PCLs), mainly differentiating mucinous from non-mucinous lesions.\n\nThe secondary objective is to evaluate the model's effectiveness in risk stratification and clinical management for patients with PCLs.",[24,25,26,27,28,29],"Pancreatic Cystic Lesion","Mucinous Cystadenoma of Pancreas","Intraductal Papillary Mucinous Neoplasm of Pancreas","Pseudocyst Pancreas","Serous Cystadenoma","Neuroendocrine Tumors, NET",[31,32,33,34,35,36,37],"pancreatic cystic lesions","artificial intelligence","endoscopic ultrasound","multimodal","differentiation","risk stratification","clinical management","RECRUITING","2026-03-05",{"date":41,"type":42},"2026-03-11","ACTUAL",{"date":44,"type":42},"2025-01-01",{"date":46,"type":20},"2026-06",{"name":48,"class":49},"Huazhong University of Science and Technology","OTHER",2,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100594074","impact-of-glp-1-receptor-agonists-on-patients-with-ipmn-100594074","NCT07014709","Impact of GLP-1 Receptor Agonists on Patients With IPMN","Impact of GLP-1 Receptor Agonists on Patients With Intraductal Papillary Mucinous Neoplasms: A Retrospective Multicentric Cohort Study","IPMN-GLP1RA","Inclusion Criteria:\n\n* \\> 18 years old\n* Radiological diagnosis of IPMN\n* Treated with GLP-1 RAs.\n* Patients must have provided prior informed consent for the use of their coded clinical data in research.\n\nExclusion Criteria:\n\n* radiological diagnosis of IPMN is unclear,\n* no documented history of GLP-1 RAs use\n* patients did not provide signed informed consent, or have documented refusal for research.",{"count":60,"type":20},30,"This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy. With the increasing use of GLP-1 RAs for managing diabetes and obesity, concerns about their potential to influence pancreatic conditions, like IPMNs, have emerged. Although GLP-1 RAs are generally safe, their effects on pre-existing pancreatic conditions remain unclear.\n\nThe study aims to evaluate whether GLP-1 RA use in IPMN patients is linked to changes in pancreatic cyst characteristics, the incidence of acute pancreatitis, variations in tumor markers, and the progression of IPMNs to high-grade dysplasia or malignancy. A retrospective analysis will be conducted using medical data from patients diagnosed with IPMNs and treated with GLP-1 RAs between 2010 and 2024 at three Swiss hospitals. Key outcomes will include radiological changes, the incidence of acute pancreatitis, and potential shifts in IPMN surveillance or need for surgical intervention",[63,64,65,26,66],"IPMN","IPMN, Pancreatic","GLP-1","Glucagon-Like Peptide-1 Receptor Agonists","NOT_YET_RECRUITING","2025-06-02",{"date":70,"type":42},"2025-06-11",{"date":72,"type":20},"2025-05-31",{"date":74,"type":20},"2026-10-31",{"name":76,"class":49},"Hôpital Fribourgeois",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":50},"100528568","feasibility-trial-of-eus-pca-in-ipmn-pancreatic-cysts-100528568","NCT06162468","Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts","Single-arm Intervention Trial of the Feasibility of Endoscopic Ultrasound-guided Pancreatic Cyst Chemoablation (EUS-PCA) Using Gemcitabine and Paclitaxel for Intraductal Papillary Mucinous Neoplasms (IPMN) in Two New Zealand Tertiary Interventional Endoscopy Centres","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Radiological diagnosis of branch duct IPMN.\n* Cyst size of 3cm or worrying growth on serial imaging.\n* Suitable to undergo endoscopy under deep sedation or general anaesthesia.\n* Willing and able to comply with all trial requirements, including treatment, timing and\u002For nature of required assessments.\n* Signed, written informed consent.\n\nExclusion Criteria:\n\n* Presence of known or suspected pancreatic cancer or pathologic lymphadenopathy.\n* Radiological diagnosis of IPMN with any of the following:\n\n  1. Main pancreatic duct dilation of \\>10 mm\n  2. Cytology with high grade dysplasia or \"suspicious for malignancy\"\n  3. Common bile duct obstruction causing jaundice\n  4. Septated cysts with \\> 4 compartments\n  5. Epithelial type mural nodules (\\> 2mm)\n  6. Lesions with thick wall\u002Fseptation (\\> 2mm)\n  7. High-grade communication with the main pancreatic duct\n  8. Previous aspiration failure due to excessive cyst fluid viscosity\n* Clinically significant laboratory abnormalities\n\n  1. INR \\>= 1.7\n  2. APTT \\> 80 secs\n  3. Platelet count \\\u003C 100 x 10E9\u002FL\n  4. ALT \\> 500 U\u002FL\n  5. Total bilirubin \\> 25 umol\u002FL\n* Evidence of pancreatitis within the last 6 months.\n* History of hypersensitivity to gemcitabine or paclitaxel.\n* Concurrent illness that may jeopardise the ability of the patient to safely undergo the procedures outlined in this protocol.\n* Any medical condition that would, at the discretion of the investigator, interfere with the completion of and\u002For participation in the protocol.\n* Presence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the trial protocol and follow-up schedule, including alcohol dependence or drug abuse.\n* Pregnancy, lactation, or inadequate contraception.",{"count":86,"type":20},20,"INTERVENTIONAL",[89],"NA","The goal of this single-arm intervention trial is to determine the feasibility of implementing endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel for intraductal papillary mucinous neoplasms (IPMN) in two New Zealand tertiary interventional endoscopy centres.",[26],"2025-04-21",{"date":94,"type":42},"2025-04-23",{"date":72,"type":20},{"date":97,"type":20},"2026-07-31",{"name":99,"class":49},"University of Auckland, New Zealand",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":77},"100570396","endocrine-metabolic-inflammatory-biomarkers-to-identify-highgrade-dysplasiainvasive-carcinoma-in-patients-with-ipmn-of-the-pancreas-100570396","NCT06706700","Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia\u002Finvasive Carcinoma in Patients with IPMN of the Pancreas","Definition of Radiological and Endocrine\u002Fmetabolic\u002Finflammatory Biomarker(s) to Identify Highgrade Dysplasia\u002Finvasive Carcinoma in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas","EMI-IPMN","cohort A: inclusion criteria:\n\n* histologically proven IPMNs with full pathological data (type of IPMNs, grade of dysplasia; for invasive IPMNs: grading, pTNM classification, presence of perineural (microvascular infiltration)\n* availability of clinical and imaging criteria for surgical resections defined by International and European guidelines (worrisome features and high-risk stigmata according to International Guidelines and absolute\u002Frelative criteria for surgery according to European guidelines\n* age ≥18 years\n\nexclusion criteria:\n\n\\- lack of preoperative clinical and radiological data according the two guidelines\n\nCohort B and C:\n\ninclusion criteria:\n\n* Age \\>= 18 years\n* Charlson comorbidity index \\\u003C7\n* indication for surgery for suspected IPMN",{"count":109,"type":20},586,"Under the hypotheses that a more accurate patients selection could limit the problem of overtreatment and that benign intraductal papillary mucinous neoplasms (IPMN) have a distinguishable Endocrine\u002FMetabolic\u002FInflammatory (EMI) profile from those with high-grade disease\u002Finvasive carcinoma, this study has three specific aims. The first aim is to evaluate and confirm the accuracy of the updated versions of International and European guidelines for the management of IPMN and it will be addressed by retrospectively applying the criteria included in the two guidelines on 350 patients with resected IPMN in order to determine the most accurate criteria to identify High Grade Dysplasia(HGD)\u002FInvasive Carcinoma (IC).\n\nThe second aim is to identify pre-operative biological and\u002For radiological\u002Fendosonographic biomarker(s) able to distinguish low- versus high-risk IPMN for cancer progression in a prospective study by enrolling a cohort of 186 (of which 145 surgically-resected) patients.\n\nThe third aim is to prospectively validate biological and\u002For radiological\u002Fendosonographic biomarker(s) (previously identified and optimized) on a new cohort of 50 patients with IPMN undergoing surgical resection.",[26,112],"Pancreatic Cyst",[114,115,116],"ipmn","intraductal papillary mucinous neoplasm of the pancreas","Pancreatic Cysts","2024-11-22",{"date":119,"type":42},"2024-11-26",{"date":121,"type":42},"2020-07-13",{"date":123,"type":20},"2025-03-31",{"name":125,"class":49},"IRCCS San Raffaele"]